References
- Arany, I. and Safi rstein, R. L. (2003) Cisplatin nephrotoxicity. Semin. Nephrol. 23, 460-464. https://doi.org/10.1016/S0270-9295(03)00089-5
- Boudonck, K. J., Mitchell, M. W., Nemet, L., Keresztes, L., Nyska, A., Shinar, D. and Rosenstock, M. (2009) Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 37, 280-292. https://doi.org/10.1177/0192623309332992
- Bylesjo, M., Rantalainen, M., Cloarec, O., Nicholson, J., Holmes, E. and Trygg, J. (2006) OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classifi cation. J. Chemom. 20, 341-351. https://doi.org/10.1002/cem.1006
- Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R. and Nicholson, J. K. (2009) Pharmacometabonomic identifi cation of a signifi cant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. USA. 106, 14728-14733. https://doi.org/10.1073/pnas.0904489106
- Clayton, T. A., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J. P., Le Net, J. L., Baker, D., Walley, R. J., Everett, J. R. and Nicholson, J. K. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077. https://doi.org/10.1038/nature04648
- Cloarec, O., Dumas, M. E., Craig, A., Barton, R. H., Trygg, J., Hudson, J., Blancher, C., Gauguier, D., Lindon, J. C., Holmes, E. and Nicholson, J. (2005) Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identifi cation from metabolic 1H NMR data sets. Anal. Chem. 77, 1282-1289. https://doi.org/10.1021/ac048630x
- Crino, L., Calandri, C., Maestri, A. and Marrocolo, F. (2001) Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer. Oncology (Williston Park) 15, 40-42.
- Davis, J. W. and Kramer, J. A. (2006) Genomic-based biomarkers of drug-induced nephrotoxicity. Expert Opin. Drug Metab. Toxicol. 2, 95-101. https://doi.org/10.1517/17425255.2.1.95
- Ebbels, T. M., Keun, H. C., Beckonert, O. P., Bollard, M. E., Lindon, J. C., Holmes, E. and Nicholson, J. K. (2007) Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J. Proteome. Res. 6, 4407-4422. https://doi.org/10.1021/pr0703021
- Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G. Jr., Levrero, M. and Wang, J. Y. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809. https://doi.org/10.1038/21690
- Hewitt, S. M., Dear, J. and Star, R. A. (2004) Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 15, 1677-1689. https://doi.org/10.1097/01.ASN.0000129114.92265.32
- Kang, J., Choi, M. Y., Kang, S., Kwon, H. N., Wen, H., Lee, C. H., Park, M., Wiklund, S., Kim, H. J., Kwon, S. W. and Park, S. (2008a) Application of a 1H nuclear magnetic resonance (NMR) metabolomics approach combined with orthogonal projections to latent structure-discriminant analysis as an effi cient tool for discriminating between Korean and Chinese herbal medicines. J. Agric. Food Chem. 56, 11589-11595. https://doi.org/10.1021/jf802088a
- Kang, J., Lee, S., Kang, S., Kwon, H. N., Park, J. H., Kwon, S. W. and Park, S. (2008b) NMR-based metabolomics approach for the differentiation of ginseng (Panax ginseng) roots from different origins. Arch. Pharm. Res. 31, 330-336. https://doi.org/10.1007/s12272-001-1160-2
- Loehrer, P. J. and Einhorn, L. H. (1984) Drugs five years later. Cisplatin. Ann. Intern. Med. 100, 704-713. https://doi.org/10.7326/0003-4819-100-5-704
- Maher, A. D., Cloarec, O., Patki, P., Craggs, M., Holmes, E., Lindon, J. C. and Nicholson, J. K. (2009) Dynamic biochemical information recovery in spontaneous human seminal fl uid reactions via 1H NMR kinetic statistical total correlation spectroscopy. Anal. Chem. 81, 288-295. https://doi.org/10.1021/ac801993m
- Maxuitenko, Y. Y., North, W. G. and Roebuck, B. D. (1997) Urinary taurine as a non-invasive marker of afl atoxin B1-induced hepatotoxicity: success and failure. Toxicology 118, 159-169. https://doi.org/10.1016/S0300-483X(96)03610-4
- Muggia, F. (2009) Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol. Oncol. 112, 275-281. https://doi.org/10.1016/j.ygyno.2008.09.034
- Nicholson, J. K., Connelly, J., Lindon, J. C. and Holmes, E. (2002) Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1, 153-161. https://doi.org/10.1038/nrd728
- Nicholson, J. K., Lindon, J. C. and Holmes, E. (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 29, 1181-1189. https://doi.org/10.1080/004982599238047
- Portilla, D., Li, S., Nagothu, K. K., Megyesi, J., Kaissling, B., Schnackenberg, L., Safi rstein, R. L. and Beger, R. D. (2006) Metabolomic study of cisplatin-induced nephrotoxicity. Kidney International 69, 2194-2204. https://doi.org/10.1038/sj.ki.5000433
- Pruefer, F. G., Lizarraga, F., Maldonado, V. and Melendez-Zajgla, J. (2008) Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J. Chemother. 20, 348-354. https://doi.org/10.1179/joc.2008.20.3.348
- Rozen, R., Tenenhouse, H. S. and Scriver, C. R. (1979). Taurine transport in renal brush-border-membrane vesicles. Biochem. J. 180, 245-248.
- Sands, C. J., Coen, M., Maher, A. D., Ebbels, T. M., Holmes, E., Lindon, J. C. and Nicholson, J. K. (2009) Statistical total correlation spectroscopy editing of 1H NMR spectra of biofl uids: application to drug metabolite profi le identifi cation and enhanced information recovery. Anal. Chem. 81, 6458-6466. https://doi.org/10.1021/ac900828p
- Smith, I. E. and Talbot, D. C. (1992) Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br. J. Cancer 65, 787-793. https://doi.org/10.1038/bjc.1992.169
- Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., Nyati, M. K., Ahsan, A., Kalyana-Sundaram, S., Han, B., Cao, X., Byun, J., Omenn, G. S., Ghosh, D., Pennathur, S., Alexander, D. C., Berger, A., Shuster, J. R., Wei, J. T., Varambally, S., Beecher, C. and Chinnaiyan, A. M. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 457, 910-914. https://doi.org/10.1038/nature07762
- Trygg, J. and Wold, S. (2002) Orthogonal projections to latent structures (O-PLS). J. Chemom. 16, 119-128. https://doi.org/10.1002/cem.695
- von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., Kerbrat, P., Sanchez Rovira, P., Wersall, P., Cleall, S. P., Roychowdhury, D. F., Tomlin, I., Visseren-Grul, C. M. and Conte, P. F. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18, 3068-3077.
- Wen, H., Kang, S., Song, Y., Sung, S. H. and Park, S. (2010a) Differentiation of cultivation sources of Ganoderma lucidum by NMR-based metabolomics approach. Phytochem. Anal. 21, 73-79. https://doi.org/10.1002/pca.1166
- Wen, H., Yoo, S. S., Kang, J., Kim, H. G., Park, J. S., Jeong, S., Lee, J. I., Kwon, H. N., Kang, S., Lee, D. H. and Park, S. (2010b) A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J. Hepatol. 52, 228-233. https://doi.org/10.1016/j.jhep.2009.11.002
- Wiklund, S., Johansson, E., Sjostrom, L., Mellerowicz, E. J., Edlund, U., Shockcor, J. P., Gottfries, J., Moritz, T. and Trygg, J. (2008) Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class Models. Anal. Chem. 80, 115-122. https://doi.org/10.1021/ac0713510
- Wishart, D. S. (2005) Metabolomics: the principles and potential applications to transplantation. Am. J. Transplant. 5, 2814-2820. https://doi.org/10.1111/j.1600-6143.2005.01119.x
- Yao, X., Panichpisal, K., Kurtzman, N. and Nugent, K. (2007) Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 334, 115-124. https://doi.org/10.1097/MAJ.0b013e31812dfe1e
Cited by
- Discovery of Potential Biomarkers with Dose- and Time-Dependence in Cisplatin-Induced Nephrotoxicity Using Metabolomics Integrated with a Principal Component-Based Area Calculation Strategy vol.29, pp.5, 2016, https://doi.org/10.1021/acs.chemrestox.5b00519
- Renal Medulla is More Sensitive to Cisplatin than Cortex Revealed by Untargeted Mass Spectrometry-Based Metabolomics in Rats vol.7, 2017, https://doi.org/10.1038/srep44804
- NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations vol.9, pp.5, 2013, https://doi.org/10.1007/s11306-013-0524-y
- NMR-Based Metabolomics in Metal-Based Drug Research vol.24, pp.12, 2011, https://doi.org/10.3390/molecules24122240
- NMR Spectroscopy for Metabolomics Research vol.9, pp.7, 2011, https://doi.org/10.3390/metabo9070123
- Urinary Metabolomic Profiling in Streptozotocin-Induced Diabetic Mice after Treatment with Losartan vol.21, pp.23, 2011, https://doi.org/10.3390/ijms21238969